.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Dow
Boehringer Ingelheim
Teva
Argus Health
Merck
Deloitte
Fish and Richardson
Harvard Business School
Express Scripts

Generated: July 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,339,489

« Back to Dashboard

Which drugs does patent 9,339,489 protect, and when does it expire?


Patent 9,339,489 protects SPRITAM and is included in one NDA.

This patent has eleven patent family members in eight countries.

Summary for Patent: 9,339,489

Title:Rapid disperse dosage form containing levetiracetam
Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
Inventor(s): Jacob; Jules (Yardley, PA), Coyle; Norman (Fort Washington, PA), West; Thomas G (Lawrenceville, NJ), Monkhouse; Donald C. (Radnor, PA), Surprenant; Henry L. (Phoenixville, PA), Jain; Nemichand B. (Princeton Junction, NJ)
Assignee: Aprecia Pharmaceuticals Company (Langhorne, PA)
Application Number:14/277,901
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-004Jul 31, 2015RXYesYes9,339,489► SubscribeY METHOD OF ADMINISTERING LEVETIRACETAM
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-002Jul 31, 2015RXYesNo9,339,489► SubscribeY METHOD OF ADMINISTERING LEVETIRACETAM
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-003Jul 31, 2015RXYesNo9,339,489► SubscribeY METHOD OF ADMINISTERING LEVETIRACETAM
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,339,489

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,669,009Rapid disperse dosage form containing levetiracetam► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,339,489

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2014228990► Subscribe
Australia2017202752► Subscribe
Canada2906029► Subscribe
China105188849► Subscribe
European Patent Office2968994► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Boehringer Ingelheim
Teva
McKesson
Johnson and Johnson
Merck
Mallinckrodt
UBS
Dow
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot